Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
The present study will be a multicenter, prospective phase II-study investigating safety and
 efficacy of the combination of auto-allo tandem stem cell transplantation in patients with
 multiple myeloma and age of >_60 years, followed by maintenance therapy with low-dose
 Thalidomide and Donor Lymphocyte Infusions.
Inclusion Criteria:

 -  Multiple Myeloma Stage II or III acc. to Salmon and Durie

 -  Patient's age 18-60 years

 -  Patient's written informed consent

 -  Women and men capable of reproduction must agree to use adequate contraceptive
 measures (condom, IUD, oral contraceptives) until three months after termination of
 treatment

 -  a maximum of eight chemotherapy cycles prior to registration (CR/ PR/ MR/ or PD)

 Exclusion Criteria:

 -  More than eight chemotherapy cycles prior to registration

 -  severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

 -  total bilirubin, SGPT or SGOT > 3 times upper the normal level

 -  Left ventricular ejection fraction < 30 %

 -  Creatinine Clearance < 30 ml/min

 -  DLCO < 35 % and/or receiving supplementary continuous oxygen

 -  Positive serology for HIV

 -  Pregnant or lactating women

 -  Participation in another trial at the time of registration

 -  Preceding autologous stem cell transplantation

 -  age > 61 years